Skip to content
Not yet recruitingNot applicable

Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression

NCT07374198 · Chinese PLA General Hospital

Closed to entry
Status
Not accepting participants
Not applicable
Phase
142
Target enrolment
Study sites

What it is testing

Summary

A Dual-Center, Randomized, Controlled, Blinded, Prospective Study on the Effects of Esketamine on Perioperative Negative Emotions in Breast Cancer Surgery Patients with Mild-to-Severe Depression

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Perioperative anxiety and depreession

    Measured over Preoperative day 1, postoperative day 3, day 7 and day 30

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
FEMALE
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Age ≥ 18 years. 2. Scheduled to undergo elective breast cancer resection surgery. 3. American Society of Anesthesiologists (ASA) physical status classification of I-III. 4. Clearly understand and voluntarily agree to participate in the study, and sign the informed consent form. 5. Female patients with mild to severe depressive symptoms (defined as a Hospital Anxiety and Depression Scale-Depression subscale score of ≥8) 6. Anticipated anesthesia duration greater than 90 minutes. Exclusion Criteria: 1. Patients with significant preoperative abnormalities in cardiac, pulmonary, hepatic, or renal function, or coagulation disorders . 2. Patients taking antipsychotics, antidepressants, or glucocorticoids, or with a history of alcohol abuse or illicit drug use . 3. Patients with an MMSE score \<18, dementia, intellectual disability, or those unable to communicate (e.g., coma, severe dementia, hearing or language impairment) . 4. Patients with a history of psychiatric or neurological disorders (e.g., schizophrenia, epilepsy, Parkinson's disease, or severe myasthenia gravis) . 5. Patients with poorly controlled or untreated hypertension (≥180/110 mmHg) . 6. Patients with elevated intracranial or intraocular pressure. 7. Patients with untreated or inadequately treated hyperthyroidism . 8. Patients with a known allergy to the drugs involved in this study . 9. Patients unable to complete the assessment scales required by this study. 10. Patients who are currently participating in other clinical trials

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07374198 on ClinicalTrials.gov →

Last updated in the registry 2026-01-28. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits